Frankfurt - Delayed Quote • EUR
G1 Therapeutics, Inc. (G1H.F)
As of 8:04 AM GMT+2. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 8 |
| Avg. Estimate | -0.99 | -0.99 | -3.63 | -3.63 |
| Low Estimate | -1.07 | -1.1 | -3.77 | -4.23 |
| High Estimate | -0.92 | -0.84 | -3.35 | -2.99 |
| Year Ago EPS | -0.31 | -0.67 | -2.62 | -3.63 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 7 | 8 |
| Avg. Estimate | 5.79M | 9.89M | 32.3M | 60.28M |
| Low Estimate | 4M | 5.69M | 14.23M | 29.29M |
| High Estimate | 8M | 14M | 42.82M | 72.9M |
| Year Ago Sales | 26.6M | 16.55M | 45.28M | 32.3M |
| Sales Growth (year/est) | -78.20% | -40.20% | -28.70% | 86.60% |
Earnings History
| CURRENCY IN USD | 9/30/2020 | 12/31/2020 | 3/31/2021 | 6/30/2021 |
|---|---|---|---|---|
| EPS Est. | -0.3 | -0.9 | -1.07 | -0.97 |
| EPS Actual | -0.31 | -0.67 | -0.65 | -0.94 |
| Difference | -0.01 | 0.23 | 0.42 | 0.03 |
| Surprise % | -3.30% | 25.60% | 39.30% | 3.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Current Estimate | -0.99 | -0.99 | -3.63 | -3.63 |
| 7 Days Ago | -0.99 | -0.99 | -3.63 | -3.63 |
| 30 Days Ago | -0.96 | -0.95 | -3.53 | -3.42 |
| 60 Days Ago | -0.95 | -0.92 | -3.49 | -3.43 |
| 90 Days Ago | -0.95 | -0.92 | -3.49 | -3.43 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2021) | Next Qtr. (Dec 2021) | Current Year (2021) | Next Year (2022) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | G1H.F | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -219.40% | -- | -- | 2.60% |
| Next Qtr. | -47.80% | -- | -- | 13.40% |
| Current Year | -38.50% | -- | -- | 5.20% |
| Next Year | 0.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Needham: Buy to Buy | 4/12/2024 |
| Reiterates | Needham: Buy to Buy | 2/28/2024 |
| Maintains | Wedbush: Outperform to Outperform | 2/13/2024 |
| Maintains | Needham: Buy to Buy | 2/13/2024 |
| Reiterates | Needham: Buy to Buy | 1/24/2024 |
| Reiterates | Needham: Buy to Buy | 12/6/2023 |